Innovative Drug Pipeline Solutions: Medicinal Chemistry, Process Chemistry, cGMP API Manufacturing. 105+ global clients. 120,000 sq.ft. facilities located in Research Triangle Park, NC USA. FDA inspected and DEA registered.

1. Innovative Drug Pipeline Solutions
Medicinal cGMP
Biological In Vitro ADMET-PK /
Chemistry & Process
Screening Pharmacology Bioanalytical
Chemistry
SCYNEXIS, Inc. delivers integrated, efficient and innovative drug discovery and development solutions to our global health and
pharmaceutical partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last
five years. Our fully-integrated contract drug outsourcing services include medicinal chemistry, advanced biological screening, in
vitro pharmacology, ADMET-PK, bioanalytical and analytical chemistry, process chemistry and scale-up and cGMP manufacturing in
our FDA-inspected facility. SCYNEXIS is headquartered in Research Triangle Park, North Carolina and occupies more than 100,000
ft2 of laboratory and office space strategically located in close proximity to RDU International Airport, UNC-Chapel Hill, Duke
University and North Carolina State University. SCYNEXIS is registered with the FDA and the DEA.
Medicinal Chemistry & Drug Discovery Selected Expertise Areas
The SCYNEXIS medicinal chemistry and drug discovery Natural Product Optimization Oncology
team has a reputation equaling the very best in the global Antifungals Kinases
pharmaceutical discovery industry. Our team has the size Antivirals Inflammation
and experience to handle projects of any complexity and Antibacterials Pain
members have been involved in the selection of multiple Antiparasitics Central Nervous System (CNS)
candidates across a variety of therapeutic areas in both Nuclear Hormones Ophthalmology
human and animal health. Ion Channels Prodrugs
Biological Screening, ADMET-PK & Bioanalytical
Core Capabilities
To support both lead optimization and candidate selection,
SCYNEXIS provides rapid generation of reliable ADMET Solubility Method Development / Qualification
and pharmacokinetic (PK) data for compounds in discovery Permeability Tissue Distribution
through pre-IND filing. SCYNEXIS rapidly screens for Caco-2 / MDCK / Transporters Pharmacokinetic Studies
properties such as metabolic stability, permeability and Metabolic Stability Prodrug Studies
Protein Binding Metabolite Identification
cytotoxicity to prioritize and differentiate lead series based
Cytotoxicity Rapid Analysis / HTS
on these and other project-specific parameters.
Cytochrome P450 Any Species / All Matrices
WWW.SCYNEXIS.COM

2. Process Chemistry & cGMP Manufacturing
The SCYNEXIS process chemistry team is capable of solving the most complex chemical development issues in a fast and efficient manner.
A distinguishing feature of our team is the equal balance between experienced process and analytical chemists. The team is focused upon
developing safe, scalable processes and has an excellent track record of providing innovative solutions to drug development companies
across the globe.
Core Capabilities
The FDA inspected our
GMP systems in 2009 and Custom Syntheses Chemical Development cGMP API Production
SCYNEXIS received no 483’s. Intermediates Scale-up of MedChem Early Clinical Supplies
Reference Standards Route Identification Small Scale Phase 3 Supplies
Preclinical Toxicology Batches Route Development Small Scale Commercial
Degradants & Impurities Process Optimization Orphan Drugs
Metabolites Novel Route Design Quality Assurance Auditing
Controlled Substances Intellectual Property Protection Fully-Qualified cGMP Facility
Analytical Development & Validation
Core Capabilities
The SCYNEXIS analytical research and development (AR&D)
Chromatography (LC/GC/TLC) Method Development
team consists of highly-experienced, industry veterans who
Normal & Reverse Phase Method Validation
develop and validate analytical methods on state-of-the-art
Forced Degradation Studies Chiral / Enantiomeric Purity
instrumentation according to the most current regulatory
Moisture Determination Preparative Isolation
guidance documents. The team is focused upon developing
Total Organic Content (TOC) Structural Identification
and validating phase-appropriate methods for the analysis of
DEA Scheduled Compounds Potential Genotoxic Impurity ID
starting materials, active pharmaceutical ingredients (APIs) and
Stability Protocols & Testing LC-MS/MS; GC/MS; NMR; UPLC
in-process synthetic intermediates.
HEOS®: A SaaS, Secure, Web-Based Software Platform For
Drug Discovery Collaborations
HEOS® suite is a comprehensive web-based drug research information In Vivo
Partners
management software that supports geographically distributed scientists
and facilitates collaboration. Chemistry
Scientists
HEOS® is seamlessly integrated with the “best” scientific expert
software currently used in the pharmaceutical industry. It allows complex
Logistical
data (biology, chemistry, analytical, safety, PK, etc.) to be exchanged, Associates
consolidated and shared rapidly and securely across multiple sites
worldwide. It provides powerful searching capabilities to combine
substructure and biological criteria, interactive SAR capabilities and decision HTS, In Vitro
Collaborators DMPK
tools to scientists and management. Contributors
From Concept To Clinic With Speed And Innovation™
SCYNEXIS, Incorporated • PO Box 12878 • Research Triangle Park • North Carolina • 27709-2878 • USA • +1.919.544.8600
WWW.SCYNEXIS.COM
©Copyright 2010, SCYNEXIS, Inc. From Concept To Clinic With Speed And Innovation is a trademark of SCYNEXIS, Inc.
SCYNEXIS and HEOS are registered trademarks of SCYNEXIS, Inc.